The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a more substantial loss in body size and enhance metabolic function, particularly co